Monthly Archive May 2018


Drew Madden: Developing Client Partnerships

As the healthcare industry changes through corporate partnerships, government regulations, and other developments, it’s more important than ever for entrepreneurs entering this field to know how to build new partnerships and develop existing ones. For companies such as CVS and Amazon, they are putting these techniques into practice, as CVS is ready to purchase insurance company Aetna and Amazon is currently purchasing pharmaceutical licenses across the United States that would allow it to sell healthcare equipment and other related items. Because of this, healthcare entrepreneurs such as Drew Madden are putting their stamp on various aspects of healthcare, especially electronic medical records.

With many aspects of healthcare in dire straits, industry experts believe the solution is to encourage more entrepreneurship in various areas. As online security becomes a bigger concern for hospitals and medical facilities everywhere, IT professionals such as Drew Madden have implemented new and innovative solutions to complex problems. This has been evident in more healthcare facilities now utilizing cloud storage, which has made electronic medical records more secure as well as accessible to both patients and their healthcare providers.

Building on his experience with Nordic Consulting Partners, Drew Madden has made it his mission to revolutionize the electronic medical records industry. Because of this, he has worked tirelessly to turn NCP into one of the world’s most authoritative companies on healthcare IT. And to show how his hard work has paid off, all one has to do is examine the numbers. Since taking over as President of NCP, Drew has helped the company expand to include more than 725 employees, grow to more than 150 clients, and have its annual revenues reach $130 million.

As the person more and more companies turn to when they need answers to the most complex electronic medical records issues, Drew Madden is looked upon as an entrepreneur who will be putting his stamp on virtually all aspects of this issue. In the months and years ahead, Drew will put his industrial engineering skills to use helping to develop software that will be secure and easy to integrate with existing healthcare systems.


” Dr Scott Rocklage’s Treatment Efforts.”

Following the media release dispensed by Scott Rocklage, research is underway to find the cure for Myotonic dystrophy type I, a genetic ailment that attacks muscles in adults when the harmful levels of the RNA are beyond limits. Expansion Therapeutic company is in charge of the campaign having contributed $55.3 million for research. Other supporting companies include 5 AM Ventures, Novartis Venture Fund, and Sanofi among many.

Expansion Therapeutic manufactures treatments that attack illnesses caused by the RNA. Most of them are repetitive and can reoccur in the families as they are resistant to drugs. They have genes that are faulty and can be inherited from one offspring to another. the disease is fatal in the subsequent progenies.

The research applied by Expansion Therapeutic is steered by Matthew D. Disney’s laboratory, the lead scientific investigator. His works have made it possible for the team to assume the position they hold. Dr Disney is confident that the treatment will be available soon to those in urgent need of treatment. He also said they would not relent until they have realised their goal.

Apart from the research team, there is a strategy in place that will see to the development of trivial molecule medication aiming RNA. The research squad is willing to continue partnering with Expansive Therapeutics in their quest of manufacturing medicines for patients without opportunities. Through the science that can end RNA stimulated diseases, the company will be able to avail treatment. Learn more:

Scott Rocklage accomplished his PhD in Chemistry from MIT after receiving a degree of science in B.A in Chemistry from the University of California. He commenced his work at 5 AM Ventures in 2003 and was promoted to the position of managing partner in 2004.

Based on his extensive knowledge of health management, Dr Scott Rocklage has contributed to the acknowledgement of various medicines by the FDA. The drugs include Teslascan, Omniscan, and Cubicin. Moreover, he has conducted clinical trials on many other treatments as well as having over thirty US patents and co-patents from his innovative work. Dr Rocklage has held various leadership and R&D positions among others.